Unreasonable Director-Related Transactions (s588FDA)

What Section 588FDA Covers

Section 588FDA covers company payments, property dispositions, securities issues and obligations to make those transactions. An obligation can be contingent. A mortgage securing another person’s debt can therefore fall within the section even before money leaves the company account.

The reasonable-person test compares the company’s benefit and detriment with the benefits received by other parties. It also takes account of other relevant circumstances. A family relationship identifies a possible recipient, while the transaction’s terms determine whether it was unreasonable. The statutory test requires both elements.

Ask what the company obtained for the value it provided. An invoice, contract or repayment record can explain a payment’s commercial purpose. A transfer description alone cannot establish that purpose.

In Vasudevan v Becon Constructions (Aust) Pty Ltd [2014] VSCA 14, Wulguru assumed liability for another company’s debt and mortgaged its land. The arrangement relieved its director of obligations under his guarantee, with no corresponding direct or indirect advantage to Wulguru. The Victorian Court of Appeal found the transaction unreasonable. The court’s reasons show why a director’s benefit can arise through a payment or security given to a third party.

Why Insolvency is Not Required

Section 588FE(6A) makes an unreasonable director-related transaction voidable without an insolvency element. It covers transactions entered into, or acts giving effect to them, within four years ending on the relation-back day. It also covers the period after that day up to the commencement of winding up.

The relation-back day is a statutory date determined by the company’s path into liquidation. Establish that date before filtering the bank ledger. A payment three years before the relation-back day can fall within the window even if the company could then pay its debts.

The four-year window identifies transactions for examination. It does not make every payment to a director recoverable. You still need evidence of the relevant benefit and unreasonableness.

Under section 588FF, the liquidator applies for court orders. Where the transaction is voidable solely on this ground, recovery targets the excess over what a reasonable person would have provided. Keep that assessment separate from recovery of a director loan account debt.

Who Counts as a Close Associate

The family categories traditionally described as close associates are now listed directly in section 588FDA. The current section 9 dictionary no longer has a separate close-associate definition. Section 588FDA names a director’s relatives and relatives of the director’s spouse, alongside directors themselves.

Section 9 defines a relative using the words “spouse, parent or remoter lineal ancestor, child or remoter issue, or brother or sister”. This includes parents and grandparents, children and grandchildren, siblings and spouses. The spouse definition includes a de facto partner. Section 9AA also recognises specified family relationships through de facto partnerships and adoption. The Act’s family definitions control who falls within these categories.

A family trust or related company is not itself a relative. Section 588FDA also reaches a person receiving on behalf of, or for the benefit of, a director or specified relative. For a trustee or company recipient, identify the person who benefits and how the transaction delivers that benefit.

A director’s shared ownership of a recipient company does not explain the whole arrangement. Inspect the debt discharged, property acquired or other benefit conferred. Transfers to a successor business can also raise the distinct questions covered in illegal phoenix activity.

Tracing Director-Related Payments in Bank Records

A consolidated ledger groups company payments by payee so you can compare recurring transfers and identify recipients for further investigation. Match those recipients with account-holder records and the director’s family relationships. Bank descriptions help locate transactions, while account ownership and supporting documents establish who received them.

In a hypothetical example, a company statement records a $40,000 debit to an account held by the director’s spouse. The spouse’s statement records the matching credit. The matching amount, timing and account details establish receipt in the spouse’s account. The next question is what the company obtained for that payment.

If the company claims the transfer repaid a loan, obtain evidence of the original advance and repayment terms. If the recipient transferred the money onward, use flow-of-funds tracing to follow the next movement. Keep the initial receipt separate from conclusions about the transaction’s commercial justification.

FinTrace saves liquidators and forensic accountants hours of statement review by turning large PDF bundles into one searchable Excel ledger and a clear findings report. The service flags suspicious transactions and follows transfers across supplied accounts. Each finding cites the source PDF filename and page, putting the supporting statements beside the analysis. The statement-analysis work costs a fraction of comparable manual review.

Build a transaction schedule showing the company debit, recipient credit and evidence of the family relationship. Attach the documents explaining the company’s benefit, then assess each transaction against section 588FDA’s reasonable-person test.

Related-Party Dealings and the Statutory Test

A related-party label identifies a connection that needs examination. It does not establish an unreasonable director-related transaction. Accounting disclosure and governance rules ask different questions from section 588FDA’s recovery test. The broader related party transactions framework covers those obligations.

For example, Chapter 2E of the Corporations Act regulates financial benefits given by public companies and controlled entities to related parties. Its approval requirements and exceptions are separate from the liquidator’s section 588FDA analysis. Apply the recipient categories and reasonable-person test to the actual transaction.

Use payment records to build a table that connects the relationship to the benefit and the company’s consideration. The following entries are hypothetical. Each needs the statements and commercial documents identified in its evidence column.

Keep an ordinary connected dealing separate from a payment the statutory evidence supports recovering. Record missing documents against the affected transaction. A schedule that shows the relationship and receipt still needs an assessment of consideration and reasonableness before the liquidator advances the claim.